| Title: |
Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment |
| Authors: |
Strikwerda-Brown, Cherie; Hobbs, Diana A.; Gonneaud, Julie; St-Onge, Frédéric; Binette, Alexa Pichet; Ozlen, Hazal; Provost, Karine; Soucy, Jean-Paul; Buckley, Rachel F.; Benzinger, Tammie L. S.; Morris, John C.; Villemagne, Victor L.; Doré, Vincent; Sperling, Reisa A.; Johnson, Keith A.; Rowe, Christopher C.; Gordon, Brian A.; Poirier, Judes; Breitner, John C. S.; Villeneuve, Sylvia; Tam, Angela; Labonte, Anne; Pichet Binette, Alexa; Faubert, Anne-Marie; Mathieu, Axel; Madjar, Cecile; Carrier, Charles Edouard; Dansereau, Christian; Kazazian, Christina; Lepage, Claude; Picard, Cynthia; Maillet, David; Michaud, Diane; Couture, Doris; Dea, Doris; Cuello, Claudio; Barkun, Alan; Evans, Alan; Courcot, Blandine; Tardif, Christine; Debacker, Clement; Jack, Clifford; Fontaine, David; Knopman, David; Multhaup, Gerhard; Near, Jamie; Leoutsakos, Jeannie-Marie; Maltais, Jean-Robert; Brandt, Jason; Pruessner, Jens |
| Source: |
JAMA Neurology ; volume 79, issue 10, page 975 ; ISSN 2168-6149 |
| Publisher Information: |
American Medical Association (AMA) |
| Publication Year: |
2022 |
| Description: |
Importance National Institute on Aging–Alzheimer’s Association (NIA-AA) workgroups have proposed biological research criteria intended to identify individuals with preclinical Alzheimer disease (AD). Objective To assess the clinical value of these biological criteria to identify older individuals without cognitive impairment who are at near-term risk of developing symptomatic AD. Design, Setting, and Participants This longitudinal cohort study used data from 4 independent population-based cohorts (PREVENT-AD, HABS, AIBL, and Knight ADRC) collected between 2003 and 2021. Participants were older adults without cognitive impairment with 1 year or more of clinical observation after amyloid β and tau positron emission tomography (PET). Median clinical follow-up after PET ranged from 1.94 to 3.66 years. Exposures Based on binary assessment of global amyloid burden (A) and a composite temporal region of tau PET uptake (T), participants were stratified into 4 groups (A+T+, A+T−, A−T+, A−T−). Presence (+) or absence (−) of neurodegeneration (N) was assessed using temporal cortical thickness. Main Outcomes and Measures Each cohort was analyzed separately. Primary outcome was clinical progression to mild cognitive impairment (MCI), identified by a Clinical Dementia Rating score of 0.5 or greater in Knight ADRC and by consensus committee review in the other cohorts. Clinical raters were blind to imaging, genetic, and fluid biomarker data. A secondary outcome was cognitive decline, based on a slope greater than 1.5 SD below the mean of an independent subsample of individuals without cognitive impairment. Outcomes were compared across the biomarker groups. Results Among 580 participants (PREVENT-AD, 128; HABS, 153; AIBL, 48; Knight ADRC, 251), mean (SD) age ranged from 67 (5) to 76 (6) years across cohorts, with between 55% (137/251) and 74% (95/128) female participants. Across cohorts, 33% to 83% of A+T+ participants progressed to MCI during follow-up (mean progression time, 2-2.72 years), compared with less than 20% of ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1001/jamaneurol.2022.2379 |
| Availability: |
https://doi.org/10.1001/jamaneurol.2022.2379; https://jamanetwork.com/journals/jamaneurology/articlepdf/2794941/jamaneurology_strikwerdabrown_2022_oi_220046_1664471641.40423.pdf |
| Accession Number: |
edsbas.67ACE9CF |
| Database: |
BASE |